
Accuray Incorporated
ARAYNASDAQHealthcareMedical - Devices
Previous close
$0.281
−$0.0114 · -3.90%
Pre-market
$0.2808
−$0.0002 · -0.07%
Aug 24, 6:38 AM ET
ARAY company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
70
Undervalued
Momentum
17
Strong Down
Sentiment
46
Mixed
Risk resilience
25
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAccuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Stephen R. LaNeve
- Listed since
- Feb 8, 2007
- Employees
- 990
Market position
Day range
Current $0.281
52-week range
Current $0.281
- Open
- $0.2928
- Previous close
- $0.2924
- Volume
- 466.71K
- 0.17× average
- Average volume
- 2.75M
- Average daily volume
- Market cap
- 33.43M USD
- Beta
- 1.39
- Market reference 1
- 50-day average
- $0.2808
- +0.07% above average
- 200-day average
- $0.558
- -49.64% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 174.26M USD
- EV / EBITDA
- -12.15×
- Earnings yield
- -155.60%
- Free cash flow yield
- 0.00%
Profitability & efficiency
- Return on equity
- -117.97%
- Return on assets
- -11.09%
- Return on invested capital
- -10.09%
Financial health
- Current ratio
- 1.5×
- Altman Z-score
- -0.68
- Piotroski F-score
- 2 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 401.95M USD | 458.51M USD | 446.55M USD | 447.61M USD | 429.91M USD |
| Cost of goods sold | 290.49M USD | 311.54M USD | 303.63M USD | 293.65M USD | 269.95M USD |
| Gross profit | 111.45M USD | 146.97M USD | 142.92M USD | 153.96M USD | 159.96M USD |
| Research and development | 37.75M USD | 47.94M USD | 49.73M USD | 57.13M USD | 57.75M USD |
| Selling, general, and administrative | 83.97M USD | 91.19M USD | 92.69M USD | 94.45M USD | 94.06M USD |
| Operating expenses | 137.9M USD | 139.13M USD | 142.42M USD | 151.58M USD | 151.81M USD |
| Interest income | — | 1.19M USD | — | — | — |
| Interest expense | 35.31M USD | 12.95M USD | 11.62M USD | 10.63M USD | 8.13M USD |
| Depreciation and amortization | — | 6.15M USD | 5.91M USD | 4.53M USD | 5.51M USD |
| Operating income | −26.44M USD | 7.84M USD | 504K USD | 2.38M USD | 8.15M USD |
| Net income | −49.19M USD | −1.59M USD | −15.55M USD | −9.28M USD | −5.35M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 27%
- 3 beats, 8 misses, 0 met estimates
- Average EPS surprise
- -173.36%
- 11 comparable reports
- Latest EPS result
- -0.02
- Estimate -0.03 · Beat by 33.33%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
13 ratingsARAY peers
ETFs holding ARAY
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI837.14K0.00%2.3T USD0.03%$378.24+0.44%
Fidelity Enhanced Small Cap ETFFESM395.53K0.01%6.03B USD0.28%$47.94+0.80%
Vanguard Extended Market ETFVXF319.06K0.00%93.7B USD0.05%$245.53+0.82%
Invesco RAFI US 1500 Small-Mid ETFPRFZ34.49K0.00%2.87B USD0.34%$55.89+0.87%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 837.14K
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Fidelity Enhanced Small Cap ETFFESM- Market value
- 395.53K
- Weight
- 0.01%
- AUM
- 6.03B USD
- Expense ratio
- 0.28%
- Price / 1D
- $47.94+0.80%
Vanguard Extended Market ETFVXF- Market value
- 319.06K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Invesco RAFI US 1500 Small-Mid ETFPRFZ- Market value
- 34.49K
- Weight
- 0.00%
- AUM
- 2.87B USD
- Expense ratio
- 0.34%
- Price / 1D
- $55.89+0.87%
Continue in GoAI
Research ARAYresearch.disclaimer





